A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice
| Autor: | Pedro H. Q. S. Medeiros, David T. Bolick, Deiziane Viana da Silva Costa, Richard L. Guerrant, Reinaldo B. Oriá, Solanka E. Ledwaba, Glynis L. Kolling, Aldo Ângelo Moreira Lima, Eileen M. Barry |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Live attenuated vaccines Immunology Biology Brief Communication medicine.disease_cause lcsh:RC254-282 Bivalent (genetics) Microbiology 03 medical and health sciences 0302 clinical medicine Shigella flexneri Immune system Antigen Enterotoxigenic Escherichia coli medicine Pharmacology (medical) 030212 general & internal medicine Clinical efficacy Pharmacology Immunogenicity lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens biology.organism_classification 3. Good health Experimental models of disease Diarrhea 030104 developmental biology Infectious Diseases Preclinical research Bacterial infection medicine.symptom lcsh:RC581-607 |
| Zdroj: | NPJ Vaccines npj Vaccines, Vol 5, Iss 1, Pp 1-5 (2020) |
| ISSN: | 2059-0105 |
| Popis: | Vaccine studies for Shigella flexneri and enterotoxigenic Escherichia coli have been impaired by the lack of optimal animal models. We used two murine models to show that a S. flexneri 2a bivalent vaccine (CVD 1208S-122) expressing enterotoxigenic Escherichia coli colonization factor antigen-I (CFA/I) and the binding subunits A2 and B of heat labile-enterotoxin (LTb) is immunogenic and protects against weight loss and diarrhea. These findings document the immunogenicity and pre-clinical efficacy effects of CVD 1208S-122 vaccine and suggest that further work can help elucidate relevant immune responses and ultimately its clinical efficacy in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|